A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Clinical trial NCT05135715 · UNKNOWN

Trial details

NCT number: NCT05135715
Sponsor: RemeGen Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma, Stage II HER2-positive Advanced Melanoma

Start date: 2022-04-19
Primary completion: 2024-12-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.